Recent News

• 09.16.2025 - Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
• 09.16.2025 - Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
• 09.08.2025 - Yasmeen Rahimi, Ph.D.
• 09.08.2025 - Yasmeen Rahimi, Ph.D.
• 09.04.2025 - Cantor Global Healthcare Conference 2025
• 09.04.2025 - Cantor Global Healthcare Conference 2025
• 08.28.2025 - Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
• 08.28.2025 - Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
• 08.13.2025 - Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.13.2025 - Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 09.09.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities